Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?

iShares U.S. Pharmaceuticals ETF (IHE) returned 50.0% over one year versus 27.4% for the broader iShares U.S. Healthcare ETF (IYH), though IHE is more concentrated, with 43.0% in Johnson & Johnson and Eli Lilly combined. Both ETFs charge a 0.37% expense ratio, while IYH is larger and more liquid with $3.9 billion in AUM versus IHE's $1.8 billion. The article favors IHE for its stronger recent multiyear annualized returns of 19.9% over three years and 11.9% over five years, compared with IHE's 10.0% and 5.5%.

Analysis

The actionable exposure is not “pharma versus healthcare” but a concentrated LLY/JNJ factor versus a more diversified healthcare mix. A basket with roughly 40%+ in LLY and JNJ will behave primarily as a GLP-1 growth-duration trade plus a defensive large-cap pharmaceutical trade; its trailing outperformance is therefore vulnerable to even a modest LLY multiple reset, reimbursement headline, or slowing prescription-growth signal. The article’s inconsistent fund descriptions and performance labels are a data-quality red flag: portfolio look-through and index methodology should be verified before using either ETF as a relative-value vehicle.

Over the next 1-3 months, the key catalyst is earnings guidance: LLY obesity/diabetes volume and pricing assumptions, JNJ litigation/reserve commentary, and MRK’s post-Keytruda growth bridge matter more than broad healthcare beta. IYH-type broad exposure should outperform if medtech and providers reaccelerate on easing rates or improved procedure volumes, while pharma concentration wins only if GLP-1 estimates continue rising. Over 6-18 months, IRA Medicare price negotiations and payer utilization management create asymmetric downside for branded-drug margin expectations, making the recent pharmaceutical momentum less durable than trailing returns imply.

Contrarian view: the apparent defensiveness of these funds understates single-name and policy correlation. A negative LLY read-through could simultaneously pressure obesity peers, large-cap pharma valuation multiples, and the concentrated ETF, while diversification into providers/devices offers a different earnings driver rather than simply lower volatility. BLK benefits only marginally from incremental assets in these products; its more relevant sensitivity is aggregate ETF flows and fee pressure, not a preference between two similarly priced niche funds.

Key Decisions for Investors

• Do not initiate a directional ETF position solely on trailing returns; verify current IHE/IYH constituent weights, index labels, and average daily dollar volume first. The article contains material classification inconsistencies, making an unverified pair trade inappropriate.
• For existing concentrated pharma exposure, reduce LLY-driven beta over the next 1-3 months by pairing long diversified healthcare exposure (IYH, subject to holdings verification) against IHE, or by trimming LLY directly. Thesis: a 10-15% LLY de-rating would have an outsized effect on the concentrated sleeve; invalidate if LLY raises forward obesity revenue guidance materially.
• Use JNJ and MRK as relatively defensive substitutes for incremental healthcare allocation rather than chasing LLY: both have lower dependence on one high-expectation growth franchise, though JNJ litigation developments and MRK’s Keytruda LOE strategy are specific downside risks. Reassess at next earnings guidance and Medicare pricing updates.
• Set an event alert around LLY earnings, payer coverage/utilization announcements, and IRA negotiation milestones. A downward revision to GLP-1 net-price or volume assumptions is the trigger to widen the long diversified-healthcare/short concentrated-pharma spread; sustained estimate upgrades would falsify the relative-value thesis.